However, in the case of incomplete resection or when somatic variants are detected in biopsy samples, the identification of pathogenic somatic variants may be relevant for more personalized epilepsy treatments, including the selection of ASM, pathway-specific treatments such as mTOR inhibitors, and therapeutic strategies for associated tumor management. This evidence concerns the gene MTOR and neoplasm.